Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate, or extent of peptide secretion. [GOC:add]
Negative regulation of peptide secretion is a complex process that involves a variety of mechanisms to control the release of peptides from cells. Peptides are short chains of amino acids that play a wide range of roles in cellular communication and function, including signaling, hormone production, and immune response. Secretion of peptides is tightly regulated to ensure proper function and to prevent harmful consequences.
One important mechanism of negative regulation is the control of **vesicle trafficking**, the process by which peptides are packaged into membrane-bound vesicles and transported to the cell surface for release. Proteins called **SNAREs** (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) play a crucial role in vesicle fusion with the plasma membrane, enabling the release of peptides. Negative regulation can occur through **inhibition of SNARE complex formation** or by **blocking the interaction of SNAREs with other regulatory proteins**. This can prevent vesicle fusion and consequently inhibit peptide secretion.
Another level of regulation involves **transcriptional control**, which regulates the synthesis of proteins involved in peptide secretion. This can include **suppression of genes encoding peptide precursors** or **downregulation of genes encoding proteins involved in vesicle formation or transport**.
**Post-translational modifications** also play a role in negative regulation. These modifications can alter the structure and function of peptide precursors, preventing their processing and secretion. For example, **phosphorylation** of a peptide precursor can inhibit its interaction with other proteins involved in secretion.
In addition, **cellular signaling pathways** can act as negative regulators of peptide secretion. Specific signaling molecules can trigger **activation of downstream effectors that suppress peptide release**. For example, **calcium signaling pathways** can inhibit vesicle fusion and peptide secretion.
Finally, **feedback mechanisms** provide a means to fine-tune peptide secretion in response to changes in the cellular environment. **Increased levels of secreted peptides can trigger pathways that inhibit further secretion**. This helps maintain homeostasis and prevent excessive peptide accumulation.
In summary, negative regulation of peptide secretion involves a multi-layered system of control that operates at various levels, including vesicle trafficking, transcriptional control, post-translational modifications, cellular signaling pathways, and feedback mechanisms. This complex and tightly regulated process ensures that peptide secretion occurs in a controlled manner to maintain cellular function and homeostasis.'
"
Protein | Definition | Taxonomy |
---|---|---|
HLA class II histocompatibility antigen gamma chain | An MHC class II histocompatibility antigen gamma chain that is encoded in the genome of human. [PRO:WCB, UniProtKB:P04233] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
crizotinib | crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER. | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |
pf-06463922 | lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer. lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein | aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles | antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |